BioXcel Therapeutics (BTAI) Competitors $1.92 -0.11 (-5.42%) Closing price 04:00 PM EasternExtended Trading$2.04 +0.12 (+6.04%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI vs. EQ, GDTC, CALC, LGVN, VYNE, QTTB, DRRX, SNYR, PULM, and ANVSShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Equillium (EQ), CytoMed Therapeutics (GDTC), CalciMedica (CALC), Longeveron (LGVN), VYNE Therapeutics (VYNE), Q32 Bio (QTTB), DURECT (DRRX), Synergy CHC Corp. (Uplisting) (SNYR), Pulmatrix (PULM), and Annovis Bio (ANVS). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Equillium CytoMed Therapeutics CalciMedica Longeveron VYNE Therapeutics Q32 Bio DURECT Synergy CHC Corp. (Uplisting) Pulmatrix Annovis Bio BioXcel Therapeutics (NASDAQ:BTAI) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings. Does the MarketBeat Community prefer BTAI or EQ? BioXcel Therapeutics received 211 more outperform votes than Equillium when rated by MarketBeat users. However, 80.00% of users gave Equillium an outperform vote while only 67.67% of users gave BioXcel Therapeutics an outperform vote. CompanyUnderperformOutperformBioXcel TherapeuticsOutperform Votes24767.67% Underperform Votes11832.33% EquilliumOutperform Votes3680.00% Underperform Votes920.00% Do analysts rate BTAI or EQ? BioXcel Therapeutics presently has a consensus price target of $42.60, suggesting a potential upside of 2,124.54%. Equillium has a consensus price target of $3.00, suggesting a potential upside of 527.62%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe BioXcel Therapeutics is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is BTAI or EQ more profitable? Equillium has a net margin of -10.05% compared to BioXcel Therapeutics' net margin of -3,119.33%. BioXcel Therapeutics' return on equity of 0.00% beat Equillium's return on equity.Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-3,119.33% N/A -105.04% Equillium -10.05%-20.68%-10.77% Do institutionals & insiders have more ownership in BTAI or EQ? 30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 27.0% of Equillium shares are held by institutional investors. 21.2% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 30.3% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger valuation & earnings, BTAI or EQ? Equillium has higher revenue and earnings than BioXcel Therapeutics. Equillium is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$2.28M2.70-$179.05M-$25.97-0.07Equillium$41.10M0.41-$13.34M-$0.23-2.08 Which has more volatility & risk, BTAI or EQ? BioXcel Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Does the media refer more to BTAI or EQ? In the previous week, Equillium had 9 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 16 mentions for Equillium and 7 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 0.65 beat Equillium's score of 0.21 indicating that BioXcel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioXcel Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBioXcel Therapeutics beats Equillium on 10 of the 19 factors compared between the two stocks. Remove Ads Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.07M$6.86B$5.61B$7.87BDividend YieldN/A2.81%5.37%4.05%P/E Ratio-0.057.3323.6218.73Price / Sales2.70206.59372.7889.10Price / CashN/A65.6738.1734.64Price / Book-0.066.146.684.14Net Income-$179.05M$142.11M$3.20B$246.93M7 Day Performance-14.51%-7.45%-5.31%-3.25%1 Month Performance-11.34%-10.65%-0.44%-6.24%1 Year Performance-95.76%-13.33%8.02%-1.44% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics4.6699 of 5 stars$1.92-5.4%$42.60+2,118.8%-95.5%$6.16M$2.28M-0.0690Earnings ReportShort Interest ↓Gap UpEQEquillium2.7563 of 5 stars$0.82+6.1%$5.00+509.8%-83.0%$29.05M$45.91M-5.8640Earnings ReportAnalyst RevisionGap UpGDTCCytoMed Therapeutics2.4616 of 5 stars$2.64+1.1%$5.00+89.4%+1.4%$28.88MN/A0.00N/AShort Interest ↓Positive NewsGap UpCALCCalciMedica2.4915 of 5 stars$2.08+3.5%$18.00+765.4%-54.1%$28.04MN/A-1.9330Earnings ReportAnalyst ForecastPositive NewsGap UpLGVNLongeveron2.1789 of 5 stars$1.86+0.5%$8.67+365.9%-52.3%$27.77M$2.39M-0.3020Short Interest ↑VYNEVYNE Therapeutics2.8763 of 5 stars$1.75+1.7%$6.88+292.9%-48.5%$26.62M$501,000.00-2.0330Short Interest ↑High Trading VolumeQTTBQ32 Bio2.4242 of 5 stars$2.18+5.3%$24.71+1,033.7%-90.3%$26.59M$-6,651,000.00-0.1539Positive NewsDRRXDURECT0.4118 of 5 stars$0.85flat$5.00+488.9%-33.7%$26.36M$8.59M-1.3980Earnings ReportSNYRSynergy CHC Corp. (Uplisting)3.1092 of 5 stars$3.02-6.8%$10.00+231.1%N/A$26.29M$26.01M0.0040Earnings ReportNews CoverageGap UpHigh Trading VolumePULMPulmatrix0.3385 of 5 stars$7.16-4.1%N/A+280.6%$26.13M$10.01M-2.7120ANVSAnnovis Bio2.2227 of 5 stars$1.81+3.4%$37.00+1,944.2%-87.4%$25.77MN/A-0.413 Remove Ads Related Companies and Tools Related Companies Equillium Alternatives CytoMed Therapeutics Alternatives CalciMedica Alternatives Longeveron Alternatives VYNE Therapeutics Alternatives Q32 Bio Alternatives DURECT Alternatives Synergy CHC Corp. (Uplisting) Alternatives Pulmatrix Alternatives Annovis Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BTAI Stock Free BTAI Stock Alerts